Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Overview status: Source-reviewed overview
What does this software do?Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Multi-region Input: Quantitative distribution information of PET radiopharmaceuticals within the patient body and CT diagnostic tomographic anatomical and photon attenuation information for the scanned region.
Who uses it?Intended users: Qualified healthcare professionals.
What does the software produce?Output: High quality functional and anatomical images; accurate registration and fusion of PET and CT images provides anatomical reference for PET findings; uExcel Focus improves the measurement accuracy of SUV and lesion volume.
What is its most important limitation?Key limitation: The system is intended to be operated by qualified healthcare professionals. Low dose CT lung cancer screening must be performed within the established inclusion criteria of programs/protocols approved and published by either a governmental body or professional medical society.
Clinical takeaway
Clinical role: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Evidence takeaway
Evidence from the reviewed source record: FDA-reviewed support consists of manufacturer non-clinical dosimetry, image-performance, software, and system testing. No independent clinical outcomes study is reported in the 510(k) summary.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
Exact purpose
uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
FDA source
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Supports patient and examination management, PET and CT data acquisition, image reconstruction, display and post-processing, quantitative PET review, PET/CT registration and fusion, networking, and filming. uExcel DPR uses pretrained neural networks for PET denoising and contrast improvement, while uExcel Focus and HYPER Focus address respiratory-motion effects.
Quantitative distribution information of PET radiopharmaceuticals within the patient body and CT diagnostic tomographic anatomical and photon attenuation information for the scanned region.
FDA source
Exact FDA submission
Checked 2026-09-19
The exact indications for use directly describe the PET radiopharmaceutical information and CT information provided by the two modalities.
High quality functional and anatomical images; accurate registration and fusion of PET and CT images provides anatomical reference for PET findings; uExcel Focus improves the measurement accuracy of SUV and lesion volume.
FDA source
Exact FDA submission
Checked 2026-09-19
The exact packet supports the image, registration/fusion, and uExcel Focus performance wording without adding unsupported review or output-object claims.
The system is intended to be operated by qualified healthcare professionals. Low dose CT lung cancer screening must be performed within the established inclusion criteria of programs/protocols approved and published by either a governmental body or professional medical society.
FDA source
Exact FDA submission
Checked 2026-09-19
The exact indications for use state the qualified-user boundary and the required approval/publication boundary for low-dose CT lung cancer screening.
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact indications for use state that the uMI Panorama combines the two imaging modalities PET and CT. Controlled directory display reconciled from exact FDA wording: PET and CT -> PET/SPECT/Nuclear Medicine.
Use these fields to structure a vendor demo, security review, and implementation estimate.
Integration
The scanner control and reconstruction environment provides data and patient management, networking, display and post-processing, and DICOM-standard image exchange.
FDA source
Exact FDA submission
Checked 2026-09-02
Confirm supported DICOM services, object types, PACS and RIS connectivity, worklist behavior, and interface versions for the installed configuration.
FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.
Training and support
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-08-13
Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.
Monitoring and change control
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-08-13
Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.
Scanner configuration
Integrated PET and 160-slice CT system with 280 mm or 350 mm PET axial field of view, a 760 mm bore, and a maximum table load of 318 kg.
exact submission · checked 2026-09-02
Confirm ordered detector coverage, table accessories, room requirements, power, cooling, shielding, and service clearances.
Provides DICOM-standard image exchange plus patient and data management, networking, image display, post-processing, and filming functions within the scanner environment.
exact submission · checked 2026-09-02
Validate modality worklist, accession and patient reconciliation, PACS routing, quantitative-image preservation, and downstream viewer compatibility.
United Imaging's current uMI Panorama family page describes 28 cm and 35 cm scalable PET axial fields of view, a 76 cm bore, 318 kg table capacity, 160 CT slices per rotation, and uExcel AI workflow features.
product family · checked 2026-09-02
Current family-page claims may span configurations or software releases; map them to the quoted and installed system before procurement or validation.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA-reviewed support consists of manufacturer non-clinical dosimetry, image-performance, software, and system testing. No independent clinical outcomes study is reported in the 510(k) summary.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
These are common procurement questions; unknown values remain visible until a source supports them.
Pricing and total cost
Vendor documentation pending
Vendor confirmation
Exact FDA submission
Checked 2026-08-13
FDA submission materials do not establish current commercial pricing. Request the pricing unit, term, minimum commitment, implementation fees, and included support from the vendor.
Reimbursement and coding
Research pending
Needs research
Exact FDA submission
Checked 2026-08-31
Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall Z-0225-2026 affects uMI Panorama 35 systems. A third-party outer cover could become trapped between the patient table and gantry and interfere with table movement. FDA lists the recall as open and classified.
FDA source
Exact product version
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact uMI Panorama 35 model and native submission match. The recall is limited to affected model 35 units and describes a mechanical or accessory-use issue, not an AI-algorithm defect.
Verify security and privacy controls: FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.
Verify training: Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.
Verify pricing and total cost: FDA submission materials do not establish current commercial pricing. Request the pricing unit, term, minimum commitment, implementation fees, and included support from the vendor.
Verify reimbursement and coding relevance: Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.
Verify local validation and lifecycle monitoring: Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
22Fields reviewed
10Source classes checked
8Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 8 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 8 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda device recall, vendor product page, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history7 sources - 3 history items
uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified...
syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for...
uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and...